.webp)
.webp)
.webp)
.webp)
Delaware has amended its Pharmacy Practice Act through Senate Bill 180, effective June 30, 2026, introducing new definitions, updated licensing requirements, and expanded obligations across nearly every entity type in the pharmaceutical supply chain.
The changes affect manufacturers, wholesale distributors, outsourcing facilities, pharmacies, and anyone designated as key personnel at a non-publicly held company.
For the complete text of the legislation, visit the Delaware SB 180 bill page.
Before getting into entity-specific requirements, several new or updated definitions in §2502 are worth understanding because they affect how Delaware classifies business activities across all license types.
Manufacturing now explicitly includes packaging, repackaging, labeling, relabeling, and promoting a commercially available product from a bulk compound for resale. If your operations touch any of these activities, Delaware considers that manufacturing.
Compounding is now formally defined and must comply with applicable USP standards. The definition clarifies that compounding includes preparation of drugs in anticipation of prescription orders based on routine prescribing patterns, but excludes anything done for sale or dispensing outside of a practitioner relationship.
Key Personnel is a new definition that will affect non-publicly held companies across all entity types. Key personnel means the designated representative or most senior individual responsible for facility operations, purchasing, and inventory control, their supervisor, and any principal or owner who directly or indirectly holds more than 10% interest in the establishment.
Action Required: All key personnel at non-publicly held companies must submit fingerprints for criminal history checks through both the Delaware State Bureau of Identification and the FBI. This applies to manufacturers, wholesale distributors, outsourcing facilities, and medical gas distributors. If your company has multiple principals or owners above the 10% threshold, each must comply individually.
Outsourcing Facility now has a formal definition in Delaware statute. To qualify, a facility must be located within the US at one address, be FDA-registered under Section 503B of the FD&C Act, be doing business within or into Delaware, and be licensed with the Delaware Board as a wholesaler before applying to become an outsourcing facility.
Under the new §2540A, manufacturers applying for or renewing a Delaware license must provide:
The expanded definition of Manufacturing is also worth reviewing. Delaware now explicitly includes packaging, repackaging, labeling, relabeling, and promoting a commercially available product from a bulk compound for resale within its definition of manufacturing. If your operations include any of these activities, confirm that your Delaware license classification reflects that.
Important: Delaware licenses now terminate automatically upon a change of ownership. There is no grace period. The license ends at the moment of the ownership change. If your company is going through or planning a change of ownership, ensure new licensing applications are filed before the change takes effect.
Wholesale distributors face formal new documentation requirements for licensure under §2540A. Applications must now include:
The new Key Personnel definition and fingerprinting requirement described above applies fully to wholesale distributors at non-publicly held companies.
Important: Like manufacturers, wholesale distributor licenses in Delaware now terminate automatically upon a change of ownership. Plan accordingly if a transaction is in progress or anticipated.
Delaware's SB 180 does not call out 3PLs as a distinct license category, but the broad language in §2540, covering anyone who manufactures, packs, packages, or distributes drugs on a wholesale basis to persons other than the ultimate consumer, would likely capture 3PL operations. The key personnel fingerprinting requirement, the designated representative requirement, and the automatic license termination upon change of ownership all apply to entities operating under this framework.
Recommended Action: 3PLs operating in or into Delaware should confirm with the Delaware Board of Pharmacy whether their operations require a wholesale distributor license under this updated framework, and ensure their key personnel are prepared for the fingerprinting requirement.
Delaware's new formal definition of Outsourcing Facility introduces a two-step licensing requirement that does not exist in most other states. Before a facility can apply for an outsourcing facility license, it must first obtain a wholesale distributor license from the Delaware Board of Pharmacy.
Once that prerequisite is met, the outsourcing facility application must include:
Action Required: If your 503B outsourcing facility ships product into Delaware and does not currently hold a Delaware wholesale distributor license, you must obtain one before you can apply for or maintain an outsourcing facility license. This is a new sequential requirement that 503Bs should address promptly.
Several changes in SB 180 affect pharmacies specifically.
Pharmacist-in-Charge (PIC): Under the updated §2526, each pharmacy may have only one pharmacist-in-charge, and that pharmacist-in-charge may only serve one pharmacy at a time. This is now explicit in Delaware statute.
Prescription Labeling: Updated §2522 requires pharmacists to ensure a label is affixed to every dispensed container. The label must contain all information required by the Board's rules and regulations. Practitioners who sell or dispense drugs directly to patients must label all drugs or provide a document that includes the patient's full name and address, the dispensing date, the practitioner's name, phone number, and address, the practitioner's DEA number for controlled substances, and the drug name, strength, dosage form, quantity, and route of administration if other than oral.
Nonresident Pharmacies: Under the updated §2535, nonresident pharmacy applicants must submit a qualifying inspection report. If the home state licensing authority has not conducted a qualifying inspection, the pharmacy must submit an inspection report from NABP's Verified Pharmacy Program or from another qualified entity as determined by the Board.
Drug Substitution: Updated §2550 clarifies the conditions under which pharmacists may substitute a therapeutically equivalent drug. Unauthorized substitution carries penalties of $500 to $1,000 in fines and potential imprisonment of 30 days to one year.
Biological Product Substitution: Under the new §2551, when a pharmacist substitutes a biological product, they must notify the prescribing practitioner of the substituted product within 10 days of dispensing. Hospital pharmacies are exempt from this notification requirement.
Emergency Refills: The new §2552 establishes that pharmacists may dispense emergency supplies of noncontrolled drugs pursuant to Board rules and regulations.
All non-publicly held companies: Key personnel fingerprinting required.
All entities: Licenses terminate automatically on change of ownership.
Manufacturers: Confirm license classification covers all manufacturing activities under the expanded definition.
Wholesale Distributors: Prepare floor plans, lease or deed documentation, and proof of home state licensure.
3PLs: Confirm licensure category with the Delaware Board of Pharmacy.
503B Outsourcing Facilities: Obtain a wholesale distributor license before applying for or maintaining an outsourcing facility license.
Pharmacies: Confirm PIC serves only one facility and review labeling, substitution, and nonresident inspection requirements.
This is a summary of the most impactful changes in Delaware SB 180 that we’ve prepared. LighthouseAI recommends that all affected entities review the full text of the bill to ensure complete compliance with the updated Delaware Pharmacy Practice Act.
Review the full text of Delaware SB 180
Delaware SB 180 is one example of how quickly state-level pharmaceutical regulations can shift across all entity types. Manually tracking changes like these across all 56 US jurisdictions is not realistic for most organizations.
LighthouseAI's Selective Notifications deliver automated regulatory monitoring alerts tailored to your license portfolio, so your team is always informed of new and changing requirements before they affect your operations.
Never miss a new or changing state licensing requirement. Request a Demo
.svg){kind=small}
